首页> 美国卫生研究院文献>Frontiers in Pediatrics >Long-Term Clinical Outcomes and Parental Satisfaction After Dextranomer/Hyaluronic Acid (Dx/HA) Injection for Primary Vesicoureteral Reflux
【2h】

Long-Term Clinical Outcomes and Parental Satisfaction After Dextranomer/Hyaluronic Acid (Dx/HA) Injection for Primary Vesicoureteral Reflux

机译:右旋糖酐/透明质酸(Dx / HA)注射治疗原发性输尿管反流的长期临床疗效和父母满意度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: Endoscopic dextranomer/hyaluronic acid (Dx/HA) injection is a common treatment for vesicoureteral reflux (VUR) with excellent reported short-term clinical success rates. Long-term outcomes are less well-defined. We assessed long-term outcomes and parental satisfaction after Dx/HA injection for primary VUR with >5-year follow-up.>Materials and Methods: Families of all patients who underwent Dx/HA injection for primary VUR at our institution between 2008 and 2012 were contacted for telephone interview. Data collected by phone included parental satisfaction and presence and severity of UTIs pre-operatively and post-operatively. Patient demographics, radiographic VUR data, need for secondary surgery, and surgical indications were obtained through chart review.>Results: Five hundred and seventy-five patients underwent Dx/HA injection for primary VUR between 2008 and 2012. Ninety-nine (17.2%) of these patients' parents were successfully contacted and interviewed. Median follow-up time from surgery to survey was 8.4 (IQR 6.8–9.6) years. Secondary surgery was performed in 13/99 (13.1%), most commonly repeat Dx/HA injection. Seven patients (7.1%) underwent secondary Dx/HA injection for persistent VUR without UTIs at a median of 0.35 (IQR 0.33–0.77) years post-operatively. Five patients (5.1%) underwent Dx/HA injection (n = 3) or ureteral reimplantation (n = 2) for VUR with febrile UTIs (fUTIs) at a median of 2.2 (IQR 1.3–5.1) years. One patient had ureteral reimplantation for symptomatic obstruction 2.8 years after initial surgery. Only 3/99 (3.0%) required open or laparoscopic surgery after Dx/HA injection. Eighty-three families (84.7%) reported ≥1 fUTIs pre-operatively. Of these, only 9/83 (10.8%) reported fUTIs post-operatively, for an overall clinical success rate of 89.2%. Clinical success was 93.1% in patients whose pre-operative fUTIs were treated outpatient and 80.0% in those hospitalized at least once for fUTI treatment pre-operatively. Ninety-four percent of parents were highly satisfied, 2.4% partially satisfied, and 3.5% dissatisfied.>Conclusions: Endoscopic injection with Dx/HA for primary VUR appears to have good long-term clinical success rates and high parental satisfaction, mirroring our previously reported short-term results. Post-operative ureteral obstruction is rare but may occur years post-operatively, justifying initial sonographic surveillance, and repeat imaging in symptomatic patients.
机译:>目的:内窥镜右旋糖酐/透明质酸(Dx / HA)注射是膀胱输尿管反流(VUR)的常见治疗方法,其短期临床成功率极高。长期结果的定义不太明确。我们对Dx / HA注射原发性VUR的长期结局和父母满意度进行了5年以上的随访。>材料和方法:所有接受Dx / HA注射原发性VUR的患者的家庭我们于2008年至2012年之间联系了我们机构进行电话采访。通过电话收集的数据包括父母的满意度以及术前和术后UTI的存在和严重程度。通过图表审查获得了患者的人口统计学资料,X线照相的VUR数据,需要进行二次手术以及手术适应症。>结果:2008年至2012年之间,有575例患者接受了Dx / HA注射以治疗原发性VUR。这些患者的父母中有99名(17.2%)已成功联系并接受了采访。从手术到调查的平均随访时间为8.4(IQR 6.8–9.6)年。二次手术以13/99(13.1%)进行,最常见的是重复Dx / HA注射。七名患者(7.1%)因持续性VUR而无UTI接受二次Dx / HA注射,手术后中位数为0.35(IQR 0.33-0.77)年。五名患者(5.1%)接受了Dx / HA注射(n = 3)或输尿管再植入(n = 2)并伴有发热性UTI(fUTIs)的VUR,中位年龄为2.2(IQR 1.3-5.1)年。一名患者在初次手术后2.8年因症状性阻塞而输尿管再植。 Dx / HA注射后仅3/99(3.0%)需进行开放式或腹腔镜手术。术前有83个家庭(84.7%)报告≥1 fUTI。其中只有9/83(10.8%)的患者术后报告了fUTI,总体临床成功率为89.2%。术前fUTI接受门诊治疗的患者的临床成功率为93.1%,至少术前接受过fUTI治疗的住院患者为80.0%。 94%的父母非常满意,部分满意的父母占2.4%,不满意的父母占3.5%。>结论:内镜注射Dx / HA治疗原发性VUR的长期临床成功率较高,父母的满意度,反映了我们先前报告的短期结果。术后输尿管梗阻很少见,但可能在术后数年发生,证明有必要进行超声检查,并对有症状的患者进行重复成像。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号